1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TaiRx, Inc.

TaiRx, Inc.

6580.TWO
TaiRx, Inc.TW flagTaipei Exchange
15.00
TWD
-0.05
- -
1.68BMarket Cap
TaiRx, Inc.
6580.TWO
(Taipei Exchange)

Recent

price

15.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
0.02
0.05
0.05
0.06
0.08
0.06
0.07
- -
Revenue per Share
-1.67
-1.97
-2.11
-3.39
-3.6
-2.37
-1.38
-2.37
-2.31
-1.26
- -
Basic EPS, GAAP
-2.34
-2.09
-2.24
-2.99
-2.8
-2.12
-1.38
-2.08
-2.12
-1.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.87
5.43
3.23
-0.15
-2.99
-0.88
-1.95
-4.33
-4.35
-4.85
- -
Book Value per Share
11.01
12.18
9.88
6.53
5.41
9.92
6
3.89
6.98
4.72
- -
Tangible Book Value per Share
56
60
62
62
61
67
91
89
92
110
- -
Basic Weighted Avg Shares
- -
- -
- -
2
3
3
5
7
5
8
28
Sales/Revenue/Turnover
- -
- -
- -
-14,342.17
-7,073.7
-4,853.29
-2,532.23
-3,077.89
-4,224.62
-1,775.29
-851.5
Operating Margin (%)
- -
- -
- -
1
4
4
4
4
3
7
8
Depreciation Expense
-93
-119
-130
-210
-218
-159
-126
-212
-212
-139
-221
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-13,960.63
-6,900.03
-4,745.04
-2,443.36
-3,056.15
-4,177.33
-1,688.58
-793.28
Profit Margin (%)
603
725
603
398
320
668
547
350
643
522
371
Working Capital
- -
- -
- -
- -
6
2
- -
12
9
6
2
LT Debt
799
921
797
593
458
798
676
479
773
649
442
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-33.56
-49.44
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.33%
-6.22%
-31.91%
Free Cash Flow
5.4%
7.59%
19.65%
Net Income, GAAP
14.8%
14.45%
59.27%
Sales/Revenue/Turnover
- -
72.39%
239.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
28

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.31
2024
- -
- -
- -
- -
-1.26
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Anixa Biosciences, Inc. (ANIX)
LakeShore Biopharma Co., Ltd (LSBCF)
H-CYTE, Inc. (HCYT)
Redwood Pharma AB (REDW.ST)
Greenwich LifeSciences, Inc. (GLSI)
Dimension Therapeutics, Inc. (DMTX)
Business
TaiRx, Inc. (6580.TWO) develops and commercializes therapeutics primarily for cancer treatment and other diseases including inflammatory bowel conditions; core products and pipeline candidates include CVM-1118 (Foslinanib), an oral anti-cancer drug in Phase II clinical trials that received U.S. FDA Orphan Drug Designation for pancreatic neuroendocrine tumors (PNETs) in January 2025 granting seven years of market exclusivity upon approval; Zelnite, the only TFDA-approved selenium injection in Taiwan for treating selenium deficiency with high-dosage labeling updated and expanded in 2024; TRX-920, an oral delivery formulation of SN-38 for colon cancer; TRX-105, a preclinical molecule for colitis and inflammatory bowel disease symptoms; TRX-ADC, an antibody-drug conjugate with novel payload for cancer; TRX-NOC and TRX-711, additional investigational oncology assets; and nodal diagnostic devices plus antibody drugs. Founded in 2011 and headquartered at 6F-1, No. 66, San-Chung Road, Nankang District, Taipei City 115602, Taiwan, the company operates in the biotechnology sector targeting oncology and supportive care markets with products sold domestically through distributors and clinical programs advancing globally. Recent developments encompass CVM-1118's Orphan Drug Designation in 2025 and Zelnite label expansion in 2024; earlier efforts include a 2022 manufacturing partnership with Bora Pharmaceuticals for CVM-1118 Phase II trials and the 2018 formation of TaiRx US joint venture with BioHealth Innovation for nodal protein therapeutics and diagnostics.